 |
|
 |
|
|
Mebeverine
|
|
| Systematic (IUPAC) name | |
| (RS)-4-(ethyl[1-(4-methoxyphenyl)propan-2-yl]amino)butyl 3,4-dimethoxybenzoate | |
| Identifiers | |
| CAS number | 2753-45-9 |
| ATC code | A03AA04 |
| PubChem | 24896829 |
| Chemical data | |
| Formula | C25H35NO5 |
| Mol. mass | 466.01004 [g/mol] |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Oral |
Mebeverine HCl is a musculotropic antispasmodic drug without atropic side-effects whose major therapeutic role is in the treatment of irritable bowel syndrome. It is also indicated for treatment of gastrointestinal spasm secondary to organic disorder. It was first registered in 1965. It is manufactured and marketed as Colofac, Duspatal and Duspatalin by Solvay Pharmaceuticals.
Mebeverine HCl presented in the United Kingdom as a (135mg) tablet. Others strength 100mg tablet, and 200mg capsule.
Contents |
Mode of Action
Mebeverine is an antimuscarinic. Mebeverine HCI belongs to a group of compounds called musculotropic antispasmodics. These compounds act directly on the gut muscles at the cellular level to relax them. Mebeverine is also an inhibitor of calcium-depot replenishment. Therefore, mebeverine has dual mode of action which normalizes the small bowel motility.
Indications
Spastic functional disturbances of the colon:
- Irritable bowel syndrome in its primary form
- Irritable bowel syndrome associated with organic lesions of the gastrointestinal tract such as; diverticulosis and diverticulitis, regional enteritis, disease of the gall bladder and gall ducts, gastric and duodenal ulcers, dysentery, and aspecific or specific inflammation of the digestive tract.
Adverse effects
Since 1978, 21 cases of severe adverse reactions to mebeverine were reported in the Netherlands. [1] Most reactions consisted of urticaria or maculopapular rash, sometimes accompanied by fever, polyarthritis, thrombopenia or angioedema.
Listed side effects
After taking Colofac Tablets 135 mg Very rarely, people taking this medicine may develop allergic reactions. These may include inflamed or reddened skin, itching or skin rashes. If you develop swelling of the face, lips and/or tongue, stop taking your tablets and contact your doctor immediately. If you notice these or any other side effects not mentioned in this leaflet, tell your doctor or a pharmacist.[2]
References
- ^ in 't Veld BA, van Puyenbroek E, Stricker BH. (1997). Hypersensitivity reactions to use of mebeverine. pp. 1392–5. Ned Tijdschr Geneeskd. 1997 Jul 12;141(28):1392-5. Hypersensitivity reactions to use of mebeverine [1] pubmed: 9380201
- ^ Colofac Patient leaflet sheet http://emc.medicines.org.uk/medicine/2531/PIL/Colofac+Tablets+135mg/
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
